We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Successful treatment of rituximab‐ and steroid‐resistant nephrotic syndrome with leukocytapheresis.
- Authors
Takakura, Maiko; Shimizu, Masaki; Mizuta, Mao; Inoue, Natsumi; Tasaki, Yuko; Ohta, Kazuhide; Furuichi, Kengo; Wada, Takashi; Yachie, Akihiro
- Abstract
Although rituximab (RTX) is a promising therapeutic agent for treating steroid‐resistant nephrotic syndrome (SRNS) resistant to various immunosuppressive agents, some patients have shown resistance to RTX. We report the case of a patient with RTX‐resistant nephrotic syndrome and SRNS who was successfully treated with leukocytapheresis (LCAP). After LCAP, there was a significant reduction in proteinuria and in the total number of lymphocytes, T cells, and HLA‐DR+‐activated T cells. Moreover, the patient became sensitive to steroids and RTX. LCAP reduced circulating immune cells including activated T cells and could be effective in treating rituximab‐resistant nephrotic syndrome and SRNS and in achieving remission of proteinuria.
- Publication
Journal of Clinical Apheresis, 2018, Vol 33, Issue 3, p409
- ISSN
0733-2459
- Publication type
Article
- DOI
10.1002/jca.21613